{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:05:11Z","timestamp":1773288311335,"version":"3.50.1"},"reference-count":20,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,6,1]]},"abstract":"<jats:p>Objective. To assess the long-term safety of hydrofluoroalkane 134a (HFA)-beclomethasone dipropionate (BDP) extrafine aerosol administered by the Autohaler compared with chlorofluorocarbon (CFC)-BDP administered by a press-and-breathe metered-dose inhaler (pMDI) and spacer (+S) in the treatment of children with asthma.<\/jats:p>\n               <jats:p>Methods. This 12-month, open-label, randomized, multicenter study enrolled 300 children who were aged 5 to 11 years and had well-controlled asthma on inhaled CFC-BDP or budesonide; 256 patients were using doses within the recommended range (200\u2013400 \u03bcg) and were analyzed separately. Patients were randomized in a 1:3 ratio to continue on CFC-BDP+S at approximately the same dose as they were using before study entry or switch to HFA-BDP at half the daily dose.<\/jats:p>\n               <jats:p>Results. Asthma control was well maintained in the HFA-BDP group as evidenced by lung function tests and asthma symptoms compared with CFC-BDP+S at approximately twice the dose. There were no significant differences between the HFA-BDP 100 to 200 \u03bcg and CFC-BDP+S 200 to 400 \u03bcg treatment groups in mean change from baseline in height (5.23 cm vs 5.66 cm at month 12, respectively) or mean growth velocity from day 1 to month 12 (5.27 cm\/y vs 5.71 cm\/y, respectively). There were no significant differences between groups in adrenal function tests or markers of bone metabolism.<\/jats:p>\n               <jats:p>Conclusions. In this long-term study in children with asthma, extrafine HFA-BDP provided long-term maintenance of asthma control at approximately half the dose compared with CFC-BDP+S. There were no clinically meaningful differences between HFA-BDP extrafine aerosol and conventional CFC-BDP+S with regard to growth or other systemic effects.<\/jats:p>","DOI":"10.1542\/peds.109.6.e92","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:17:55Z","timestamp":1092442675000},"page":"e92-e92","source":"Crossref","is-referenced-by-count":50,"title":["Growth, Systemic Safety, and Efficacy During 1 Year of Asthma Treatment With Different Beclomethasone Dipropionate Formulations: An Open-Label, Randomized Comparison of Extrafine and Conventional Aerosols in Children"],"prefix":"10.1542","volume":"109","author":[{"given":"S\u00f8ren","family":"Pedersen","sequence":"first","affiliation":[{"name":"Paediatrisk Afdeling, Kolding Sygehus, Kolding, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Warner","sequence":"additional","affiliation":[{"name":"Department of Child Health, Southampton General Hospital, Southampton, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Wahn","sequence":"additional","affiliation":[{"name":"Department of Pediatric Pneumology and Immunology, Charite\u0301, Humboldt-University, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris","family":"Staab","sequence":"additional","affiliation":[{"name":"Department of Pediatric Pneumology and Immunology, Charite\u0301, Humboldt-University, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muriel","family":"Le Bourgeois","sequence":"additional","affiliation":[{"name":"Service de Pneumologie et D\u2019Allergologie Pediatriques, Groupe Hopitalier Necker Enfants Malades, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Van Essen-Zandvliet","sequence":"additional","affiliation":[{"name":"Asthma Center Heideheuvel, Hilversum, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujata","family":"Arora","sequence":"additional","affiliation":[{"name":"3M Pharmaceuticals, St Paul, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley J.","family":"Szefler","sequence":"additional","affiliation":[{"name":"National Jewish Medical and Research Center, Denver, Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the Pediatric Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2002,6,1]]},"reference":[{"key":"2021121006262070400_R1","doi-asserted-by":"crossref","unstructured":"Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med.1998;157:S1\u2013S53","DOI":"10.1164\/ajrccm.157.3.157315"},{"key":"2021121006262070400_R2","unstructured":"Dolovich M, Rhem R, Gerraid L, Coates G. Lung deposition of coarse CFC vs fine HFA pMDI aerosols of beclomethasone dipropionate (BDP) in asthma [abstract]. Am J Respir Crit Care Med.2000;161:A33"},{"key":"2021121006262070400_R3","doi-asserted-by":"crossref","unstructured":"Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J.1998;12:1346\u20131353","DOI":"10.1183\/09031936.98.12061346"},{"key":"2021121006262070400_R4","doi-asserted-by":"crossref","unstructured":"Busse WW, Brazinsky S, Jacobson K, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol.1999;104:1215\u20131222","DOI":"10.1016\/S0091-6749(99)70016-3"},{"key":"2021121006262070400_R5","doi-asserted-by":"crossref","unstructured":"Davies RJ, Stampone P, O\u2019Conner BJ. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose. Respir Med.1998;92(suppl A):23\u201331","DOI":"10.1016\/S0954-6111(98)90214-1"},{"key":"2021121006262070400_R6","doi-asserted-by":"crossref","unstructured":"Gross G, Thompson P, Chervinsky P, Vanden Burgt J. HFA-134a BDP, 400 \u03bcg, is as effective as CFC-BDP, 800 \u03bcg, for the treatment of moderate asthma. Chest.1999;115:343\u2013351","DOI":"10.1378\/chest.115.2.343"},{"key":"2021121006262070400_R7","doi-asserted-by":"crossref","unstructured":"Fireman P, Prenner B, Vinken W, Demedts M, Cohen R. Long-term safety and efficacy of CFC-free beclomethasone dipropionate extrafine aerosol. Ann Allergy Asthma Immunol.2001;86:557\u2013565","DOI":"10.1016\/S1081-1206(10)62905-5"},{"key":"2021121006262070400_R8","doi-asserted-by":"crossref","unstructured":"International Consensus Report on Diagnosis and Management of Asthma. International Asthma Management Project. Allergy.1992;47(suppl):1\u201361","DOI":"10.1111\/j.1398-9995.1992.tb00952.x"},{"key":"2021121006262070400_R9","doi-asserted-by":"crossref","unstructured":"Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child.1976;51:170\u2013179","DOI":"10.1136\/adc.51.3.170"},{"key":"2021121006262070400_R10","doi-asserted-by":"crossref","unstructured":"Broid J, Soferman R, Kivity S, et al. Low-dose adrenocorticotropin test reveals impaired adrenal function in patients taking inhaled corticosteroids. J Clin Endocrinol Metab.1995;80:1243\u20131246","DOI":"10.1210\/jcem.80.4.7714095"},{"key":"2021121006262070400_R11","unstructured":"Crowley S, Hindmarsh PC, Honour J, Brook CGD. Failure of the short synacthen test to detect adrenal insufficiency in children on inhaled steroids. J Endocrinol.1992;132(suppl):95"},{"key":"2021121006262070400_R12","unstructured":"National Center for Health Statistics. Growth curves for children birth-18 years. Washington DC: National Center for Health Statistics; 1977. DHEW Publ. No. 78-1650"},{"key":"2021121006262070400_R13","doi-asserted-by":"crossref","unstructured":"Karlberg J, Gelander L, Albertsson-Wikland K. Distinctions between short- and long-term human growth studies. Acta Paediatr.1993;82:631\u2013634","DOI":"10.1111\/j.1651-2227.1993.tb12779.x"},{"key":"2021121006262070400_R14","doi-asserted-by":"crossref","unstructured":"Pedersen S. Do inhaled corticosteroids inhibit growth in children?Am J Respir Crit Care Med.2001;164:521\u2013535","DOI":"10.1164\/ajrccm.164.4.2101050"},{"key":"2021121006262070400_R15","doi-asserted-by":"crossref","unstructured":"Van Bever HP, Desager KN, Lijssens N, Weyler JJ, Du Caju MV. Does treatment of asthmatic children with inhaled corticosteroids affect their adult height?Pediatr Pulmonol.1999;27:369\u2013375","DOI":"10.1002\/(SICI)1099-0496(199906)27:6<369::AID-PPUL2>3.0.CO;2-0"},{"key":"2021121006262070400_R16","doi-asserted-by":"crossref","unstructured":"Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med.2000;343:1064\u20131069","DOI":"10.1056\/NEJM200010123431502"},{"key":"2021121006262070400_R17","doi-asserted-by":"crossref","unstructured":"Childhood Asthma Management Program Research Group. Long-term effect of budesonide or nedocromil in children with asthma. N Engl J Med.2000;343:1054\u20131063","DOI":"10.1056\/NEJM200010123431501"},{"key":"2021121006262070400_R18","doi-asserted-by":"crossref","unstructured":"Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med.1994;88:373\u2013381","DOI":"10.1016\/0954-6111(94)90044-2"},{"key":"2021121006262070400_R19","doi-asserted-by":"crossref","unstructured":"Merkus PJ, van Essen-Zandvliet EE, Duiverman EJ, van Houwelingen HC, Kerrebijn KF, Qunjer PH. Long-term effect of inhaled corticosteroids on growth rate in adolescents with asthma. Pediatrics.1993;91:1121\u20131126","DOI":"10.1542\/peds.91.6.1121"},{"key":"2021121006262070400_R20","doi-asserted-by":"crossref","unstructured":"Norjavaara E, Gerhardsson de Verdier M, Lindmark B. Reduced height in Swedish men with asthma at the age of conscription for military service. J Pediatr.2000;137:25\u201329","DOI":"10.1067\/mpd.2000.107384"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/109\/6\/e92\/995803\/pe0602000e92.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/109\/6\/e92\/995803\/pe0602000e92.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T14:48:18Z","timestamp":1639147698000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/109\/6\/e92\/64219\/Growth-Systemic-Safety-and-Efficacy-During-1-Year"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6,1]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2002,6,1]]},"published-print":{"date-parts":[[2002,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.109.6.e92","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,6,1]]}}}